PMADS

Id:	acc4712
Group:	1sens
Protein:	TGF-beta
Gene Symbol:	TGFB1
Protein Id:	P01137
Protein Name:	TGFB1_HUMAN
PTM:	phosphorylation
Site:	unclear
Site Sequence:
Disease Category:	Respiratory system diseases
Disease:	Pulmonary Fibrosis
Disease Subtype:	Idiopathic Pulmonary Fibrosis
Disease Cellline:	NHLF、DHLF、LL29
Disease Info:
Drug:	Biochanin-A(BCA)
Drug Info:	Biochanin-A (BCA) is a natural isoflavone with potential health - promoting properties. It may have beneficial effects on various physiological functions.
Effect:	inhibit
Effect Info:	BCA treatment can significantly inhibit the phosphorylation levels of TGF-beta and its downstream Smad2/3 proteins in lung tissues and alleviate the pathological abnormalities of lung tissues induced by BLM.
Note:
Score:	4.0
Pubmed(PMID):	32781391
Sentence Index:	32781391_13
Sentence:	"In addition, BCA treatment significantly (p < 0.001) attenuated the TGF-beta1/BLM-mediated increase of TGF-beta/Smad2/3 phosphorylation and resulted in the reduction of pathological abnormalities in lung tissues determined by histopathology observations."

Sequence & Structure:

MPPSGLRLLPLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	4	-	myelodysplastic syndrome	EMA DailyMed
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	4	Not yet recruiting	myelodysplastic syndrome	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	4	-	anemia (phenotype)	ATC EMA
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	4	-	Thalassemia	DailyMed
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	4	-	anemia	DailyMed
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	4	-	Beta-thalassemia	EMA
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	3	Active, not recruiting	myelodysplastic syndrome	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	3	Completed	myelodysplastic syndrome	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	3	Recruiting	myelodysplastic syndrome	ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	3	Active, not recruiting	non-small cell lung carcinoma	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	3	Recruiting	myeloproliferative disorder	ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	3	Active, not recruiting	lung cancer	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	3	Completed	Beta-thalassemia	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	3	Recruiting	Beta-thalassemia	ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	2	Terminated	head and neck squamous cell carcinoma	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	2	Active, not recruiting	myelodysplastic syndrome	ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	2	Completed	myelodysplastic syndrome	ClinicalTrials ClinicalTrials
TGFB1	LUSPATERCEPT	Transforming growth factor beta inhibitor	2	Recruiting	myelodysplastic syndrome	ClinicalTrials
TGFB1	LY-2382770	Transforming growth factor beta-1 inhibitor	2	Terminated	diabetic nephropathy	ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	2	Active, not recruiting	colorectal adenocarcinoma	ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	2	Recruiting	mesothelioma	ClinicalTrials
TGFB1	FRESOLIMUMAB	Transforming growth factor beta-1 inhibitor	2	Completed	malignant pleural mesothelioma	ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	2	Completed	cervical adenocarcinoma	ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	2	Recruiting	esophageal carcinoma	ClinicalTrials
TGFB1	BINTRAFUSP ALFA	Transforming growth factor beta binding agent	2	Terminated	non-small cell lung carcinoma	ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

TGFB1I1-Ser122
Cancer	Intensity
BRCA	-0.189
COAD	0.038
HGSC	1.368
ccRCC
GBM
HNSC
LUAD
LUSC	0.214
non_ccRCC
PDAC
UCEC	-1.431

TGFB1I1-Ser137
Cancer	Intensity
BRCA	0.832
COAD	-0.065
HGSC	-1.289
ccRCC	0.452
GBM	0.44
HNSC	0.493
LUAD	0.476
LUSC	0.808
non_ccRCC	-0.423
PDAC	0.631
UCEC	-2.355

TGFB1I1-Ser140
Cancer	Intensity
BRCA	2.039
COAD	-1.16
HGSC
ccRCC	0.162
GBM	0.544
HNSC	0.3
LUAD	-0.461
LUSC	-0.856
non_ccRCC
PDAC	0.415
UCEC	-0.984

TGFB1I1-Ser141
Cancer	Intensity
BRCA	1.831
COAD	-0.03
HGSC	-1.276
ccRCC	0.271
GBM	0.402
HNSC	0.593
LUAD	-0.052
LUSC	-0.552
non_ccRCC
PDAC	0.507
UCEC	-1.694

TGFB1I1-Ser143
Cancer	Intensity
BRCA
COAD	-0.023
HGSC	0.264
ccRCC	0.424
GBM	0.701
HNSC	0.115
LUAD	0.293
LUSC	0.465
non_ccRCC	-0.529
PDAC	0.906
UCEC	-2.616

TGFB1I1-Ser150
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.265
GBM
HNSC
LUAD	0.729
LUSC	0.359
non_ccRCC	-0.584
PDAC	0.964
UCEC	-1.732

TGFB1I1-Ser153
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

TGFB1I1-Ser164
Cancer	Intensity
BRCA	-0.318
COAD	0.266
HGSC	1.32
ccRCC	0.645
GBM	0.58
HNSC	0.438
LUAD	0.629
LUSC	0.002
non_ccRCC	-0.668
PDAC	-0.419
UCEC	-2.475

TGFB1I1-Ser166
Cancer	Intensity
BRCA
COAD	-0.035
HGSC	1.036
ccRCC	0.344
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-1.344

TGFB1I1-Ser186
Cancer	Intensity
BRCA
COAD	-1.442
HGSC	1.127
ccRCC	-0.173
GBM	0.773
HNSC	0.412
LUAD	0.548
LUSC
non_ccRCC
PDAC
UCEC	-1.245

TGFB1I1-Ser187
Cancer	Intensity
BRCA
COAD	-1.361
HGSC	1.197
ccRCC	-0.081
GBM	0.653
HNSC	0.3
LUAD	0.631
LUSC
non_ccRCC
PDAC
UCEC	-1.339

TGFB1I1-Ser192
Cancer	Intensity
BRCA	1.06
COAD	-0.327
HGSC	0.999
ccRCC	-0.308
GBM	0.669
HNSC	0.411
LUAD	0.541
LUSC	0.25
non_ccRCC	-1.307
PDAC	0.236
UCEC	-2.223

TGFB1I1-Ser194
Cancer	Intensity
BRCA	1.046
COAD	-0.247
HGSC	0.702
ccRCC	-0.353
GBM	0.81
HNSC	0.484
LUAD	0.685
LUSC	0.206
non_ccRCC	-0.978
PDAC	0.065
UCEC	-2.422

TGFB1I1-Ser203
Cancer	Intensity
BRCA
COAD	0.124
HGSC	0.575
ccRCC	0.251
GBM
HNSC	0.683
LUAD	0.496
LUSC	0.888
non_ccRCC	-1.522
PDAC	0.404
UCEC	-1.9

TGFB1I1-Ser213
Cancer	Intensity
BRCA
COAD	0.44
HGSC
ccRCC	-0.21
GBM
HNSC	0.745
LUAD	0.106
LUSC	1.43
non_ccRCC	-1.23
PDAC
UCEC	-1.281

TGFB1I1-Ser216
Cancer	Intensity
BRCA	2.302
COAD	-0.114
HGSC
ccRCC	-0.232
GBM
HNSC	0.585
LUAD	0.239
LUSC	-0.272
non_ccRCC	-0.626
PDAC	-0.96
UCEC	-0.921

TGFB1I1-Ser284
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

TGFB1I1-Ser37
Cancer	Intensity
BRCA
COAD	0.516
HGSC	-1.153
ccRCC	0.637
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

TGFB1I1-Ser383
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.287
GBM
HNSC	1.034
LUAD	0.72
LUSC	0.826
non_ccRCC	-1.045
PDAC	-1.248
UCEC

TGFB1I1-Ser403
Cancer	Intensity
BRCA	0.484
COAD	0.246
HGSC	0.775
ccRCC	0.298
GBM	0.467
HNSC	0.776
LUAD	0.742
LUSC	0.527
non_ccRCC	-1.804
PDAC	-0.562
UCEC	-1.949

TGFB1I1-Ser418
Cancer	Intensity
BRCA	1.097
COAD	0.936
HGSC
ccRCC	0.396
GBM
HNSC
LUAD	0.451
LUSC	0.113
non_ccRCC	-1.359
PDAC	0.008
UCEC	-1.643

TGFB1I1-Ser68
Cancer	Intensity
BRCA	-1.283
COAD	-1.455
HGSC	-0.396
ccRCC	-0.527
GBM
HNSC	1.256
LUAD	-0.175
LUSC	0.794
non_ccRCC	0.17
PDAC	1.592
UCEC	0.024

TGFB1I1-Ser80
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.674
GBM
HNSC
LUAD	0.476
LUSC
non_ccRCC
PDAC
UCEC	-1.149

TGFB1I1-Ser81
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

TGFB1I1-Ser82
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

TGFB1I1-Ser83
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

TGFB1I1-Thr155
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

TGFB1I1-Thr188
Cancer	Intensity
BRCA
COAD	-0.977
HGSC	1.075
ccRCC	-0.163
GBM	0.745
HNSC	0.443
LUAD	0.552
LUSC
non_ccRCC
PDAC
UCEC	-1.675

TGFB1I1-Thr33
Cancer	Intensity
BRCA	0.738
COAD	0.119
HGSC	-2.586
ccRCC	0.339
GBM	0.966
HNSC	0.334
LUAD	0.272
LUSC	0.485
non_ccRCC	-0.437
PDAC	0.615
UCEC	-0.845

TGFB1I1-Thr407
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

TGFB1I1-Tyr279
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

TGFB1I1-Tyr38
Cancer	Intensity
BRCA
COAD	0.382
HGSC	-1.49
ccRCC	0.449
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.658

TGFB1I1-Tyr60
Cancer	Intensity
BRCA	-0.241
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	1.099
LUSC	-0.857
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb